AbbVie accused a former employee and a rival oncology developer of stealing trade secrets about its antibody-drug conjugate programs.
The pharma giant on Friday filed suit in California federal court against Adcentrx and scientist Danny Lee, who left AbbVie in 2021 to join Adcentrx. The complaint alleges that Lee was “in a unique position to know information a competitor would want to know” about AbbVie’s confidential microtubule inhibitor (MTi) ADC program. The company claimed Lee took that information to Adcentrx, which used it to “jump-start” its own ADC program, now in Phase I.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.